SHC314
MISSION® 1X LacO Inducible TurboGFP™ shRNA Control Plasmid DNA
shRNA sequence targeting tGFP
Synonym(s):
MISSION® Control Vectors
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
UNSPSC Code:
12352200
MDL number:
Product Name
MISSION® 1X LacO Inducible TurboGFP™ shRNA Control Plasmid DNA, shRNA sequence targeting tGFP
product line
MISSION®
shipped in
dry ice
storage temp.
−20°C
Application
To see more application data, protocols, vector maps visit sigma.com/shrna.
General description
Sigma® is proud to offer IPTG-inducible vectors as the latest development from our continued partnership in TRC.
The pLKO vector has been redesigned to contain a LacI (repressor) and a modified human U6 shRNA promoter with LacO (operator) sequences. In the absence of IPTG (isopropyl-Β-D-thio-galactoside), an analogue of lactose, LacI binds to LacO preventing expression of the shRNA. When IPTG is present, the allosteric LacI repressor changes conformation, releasing itself from lacO modified human U6 promoter, and subsequently allows expression of the shRNA.
The MISSION 1X LacO Inducible TurboGFP™ shRNA Control is a 8,684 base pair lentivirus plasmid vector that contains an shRNA sequence targeting TurboGFP. The TurboGFP shRNA Control Vector is useful as a positive knockdown control in experiments using the MISSION TurboGFP positive control vector or in cell lines expressing TurboGFP. TurboGFP is an improved variant of the green fluorescent protein copGFP cloned from copepoda Pontellina plumata.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids.The TurboGFP shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
The pLKO vector has been redesigned to contain a LacI (repressor) and a modified human U6 shRNA promoter with LacO (operator) sequences. In the absence of IPTG (isopropyl-Β-D-thio-galactoside), an analogue of lactose, LacI binds to LacO preventing expression of the shRNA. When IPTG is present, the allosteric LacI repressor changes conformation, releasing itself from lacO modified human U6 promoter, and subsequently allows expression of the shRNA.
The MISSION 1X LacO Inducible TurboGFP™ shRNA Control is a 8,684 base pair lentivirus plasmid vector that contains an shRNA sequence targeting TurboGFP. The TurboGFP shRNA Control Vector is useful as a positive knockdown control in experiments using the MISSION TurboGFP positive control vector or in cell lines expressing TurboGFP. TurboGFP is an improved variant of the green fluorescent protein copGFP cloned from copepoda Pontellina plumata.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids.The TurboGFP shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Legal Information
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Sigma is a registered trademark of Sigma-Aldrich Co. LLC
TurboGFP is a trademark of Evrogen Co.
Storage Class
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R Zufferey et al.
Journal of virology, 72(12), 9873-9880 (1998-11-13)
In vivo transduction of nondividing cells by human immunodeficiency virus type 1 (HIV-1)-based vectors results in transgene expression that is stable over several months. However, the use of HIV-1 vectors raises concerns about their safety. Here we describe a self-inactivating
R Zufferey et al.
Nature biotechnology, 15(9), 871-875 (1997-11-05)
Retroviral vectors derived from lentiviruses such as HIV-1 are promising tools for human gene therapy because they mediate the in vivo delivery and long-term expression of transgenes in nondividing tissues. We describe an HIV vector system in which the virulence
Sheila A Stewart et al.
RNA (New York, N.Y.), 9(4), 493-501 (2003-03-22)
Genome-wide genetic approaches have proven useful for examining pathways of biological significance in model organisms such as Saccharomyces cerevisiae, Drosophila melanogastor, and Caenorhabditis elegans, but similar techniques have proven difficult to apply to mammalian systems. Although manipulation of the murine
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service